Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, and the Asia Pacific. The company is involved in hemp growing operations, outsourced CBD extraction, and cannabidiol (CBD) product sales activities, as well as the development and commercialization of its therapeutic products. Its products include anibidiol, a natural complementary feed product for companion animals; and cannaQIX, a nutraceutical product containing organic hemp extract with CBD vitamins and zinc to reduce stress and support mental and nervous functions in humans, as well as topical and skin care products. The company also offers various nutraceutical products, such as cannaQIX®nite to aid sleep; cannaPEAL to introduce various markets to the benefits of hemp seed oil-based products; and cannaDOL to provide relief to athletes in the form of a topical application. In addition, it imports and sells its medicinal cannabis product, cannaQIX50 to patients in Brazil. Creso Pharma Limited has a strategic collaboration agreement with Hempmate AG Switzerland and Burleigh Heads Cannabis Pty Ltd. The company was incorporated in 2015 and is headquartered in Sydney, Australia.